X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
Globe Newswire (Wed, 5-Nov 4:01 PM ET)
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 5-Nov 7:00 AM ET)
Market Chameleon (Fri, 24-Oct 6:30 AM ET)
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
X4 Pharmaceuticals trades on the NASDAQ stock market under the symbol XFOR.
As of January 30, 2026, XFOR stock price climbed to $3.74 with 191,639 million shares trading.
XFOR has a beta of 1.01, meaning it tends to be more sensitive to market movements. XFOR has a correlation of 0.02 to the broad based SPY ETF.
XFOR has a market cap of $327.01 million. This is considered a Small Cap stock.
Last quarter X4 Pharmaceuticals reported $2 million in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-136,350 and exceeded earnings estimates by $.13.
In the last 3 years, XFOR traded as high as $77.25 and as low as $1.35.
The top ETF exchange traded funds that XFOR belongs to (by Net Assets): VTI, VXF, ITWO, URTY.
XFOR has underperformed the market in the last year with a return of -83.0%, while the SPY ETF gained +16.1%. In the last 3 month period, XFOR fell short of the market, returning 0.0%, while SPY returned +0.8%. However, in the most recent 2 weeks XFOR has outperformed the stock market by returning +3.3%, while SPY returned -0.2%.
XFOR support price is $3.57 and resistance is $3.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XFOR shares will trade within this expected range on the day.
